Navtemadlin Reduces Markers of Disease Burden in Relapsed/Refractory Myelofibrosis
Treatment with navtemadlin lowered the levels of biomarkers of disease burden in patients with relapsed/refractory myelofibrosis.
Related Articles
What is Follicular Lymphoma and Why Are Better Treatments Needed?
CURE® spoke with an expert about follicular lymphoma, a disease that is still considered incurable.
SABCS 2024 Archives – VJOncology
VJOncology are excited to attend the upcoming 47th San Antonio Breast Cancer Symposium (SABCS) 2024, bringing you the highly-anticipated trial data and insightful perspectives from…
Explaining cancer to kids: tips from a child life specialist
Cancer can be tough to explain to kids, but child life specialists can help patients and their families communicate difficult details with care, clarity and…
High5 Oncology TV: SABCS 2024
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend. Jetzt gleich den Fragebogen ausfüllen! Durch…
FDA Grants Accelerated Approval to Encorafenib/Cetuximab/Chemo Combo in BRAF V600E+ mCRC
The combination of encorafenib, cetuximab, and mFOLFOX6 has gained accelerated approval from the FDA for the treatment of patients with metastatic colorectal cancer with a…
FDA Approval: TTFields for NSCLC | IASLC
Tumor Treating Fields (TTFields) is a non-invasive cancer treatment that uses alternating electric fields to disrupt the ability of cancer cells to divide. TTFi …
Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC
CheckMate 73L missed its primary end point of PFS in advanced unresectable stage III non–small cell lung cancer.
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Year in Review: What Themes Emerged in Cancer Research in 2024?
Several themes emerged in cancer research in 2024, including FDA-approved first-in-class therapeutics, advances in cancer vaccines, and more.
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children’s Oncology Group ADVL1823)
PURPOSEThe TRK inhibitor larotrectinib is US Food and Drug Administration approved for NTRK fusion–positive solid tumors that lack a satisfactory alternative or have progressed after…
